EFFISSIMO-CAPITAL-MGMT
1.3.2021 08:02:12 CET | Business Wire | Press release
Effissimo Capital Management (“Effissimo”), the largest shareholder of Toshiba Corporation (“Toshiba”) (TYO:6502) through the funds it manages, today released a presentation explaining the reasons behind its proposal for an independent investigation into reported irregularities surrounding Toshiba’s July 2020 Annual General Meeting of Shareholders (“AGM”). Effissimo’s proposal will be voted on by Toshiba’s shareholders at an extraordinary shareholders meeting scheduled for March 18, 2021.
The full proposal in English can be found here .
Supplementing its letter to shareholders dated February 24, 2021, Effissimo’s presentation explains its proposal for an independent investigation into the irregular handling of shareholder voting and shareholder pressure at the closely contested AGM, which Toshiba’s conflicted Audit Committee’s self-audit fails to address.
The presentation provides data showing discrepancies in the claimed delivery times of mailed ballots said by Toshiba’s vote tabulator to have been delivered past the AGM deadline and not counted. It also examines the artificially limited scope and conclusions of Toshiba’s Audit Committee’s investigations into shareholder pressure and vote tampering allegations.
Finally, the presentation provides a detailed historical context of chronic governance and oversight dysfunction at Toshiba that has persisted despite the installation of new management in 2017.
Vote Delivery & Tabulation
- Inexplicable Delay in Ballot Delivery: Effissimo’s own field tests and review of other Japanese companies’ AGMs confirm Japan Post, in accordance with its own service guidelines, normally takes at most three days to deliver domestic mail. But Toshiba’s vote tabulator insists that it took four days, in breach of Postal Law, for ballots to be delivered.
- Uncounted Ballots: There are still nearly 1,000—but possibly more than 1,600—additionally reported ballots that have yet to be audited by the Audit Committee due to claims they were delivered too late to be counted. These ballots should have ordinarily arrived prior to the vote deadline, absent the inexplicable delay in ballot delivery.
- Treatment of Blank Ballots: Mailed ballots made up more than one-third of Toshiba’s quorum at the AGM – a substantial portion of shareholder participation. Roughly 17% of ballots were blank, which Toshiba treated as favorable to management. While lawful, this is clearly an anti-dissident practice that Toshiba could have abandoned after a shareholder proposal in this regard back in 2015.
Shareholder Pressure
- Decline in Shareholder Participation: In a closely contested vote that attracted intense interest and attention, participation at the AGM declined by three percentage points year-over-year, providing grounds for suspicion that voter suppression in fact occurred.
- Multiple Institutional Investors Absent from AGM: Credible media outlets have reported that shareholders were “pressured” and/or “threatened” with a probe if they voted against Toshiba management. Toshiba’s voting records indicate that some institutional shareholders that normally vote as a matter of course did not vote at the AGM. Effissimo’s confidential survey confirmed that multiple shareholders were pressured.
Although it may appear complex, the heart of issue is simple. Effissimo believes there should be an independent investigation as opposed to a self-audit by a conflicted Audit Committee.
The Audit Committee, chaired by a director whose reappointment was opposed by more than 40 percent of shareholders at the AGM, is conflicted and is naturally reticent to conduct an uninhibited investigation of possible wrongdoing at the AGM. This conflict manifests itself in the Audit Committee’s reviews and investigations, which we suspect are deliberately limited in scope at the outset to produce a pre-determined result.
The right to vote is what is at stake. Shareholders must not passively accept the Board’s explanations at face value and allow the status quo of weak governance to persist. Failure to perform a thorough and independent investigation will set a harmful precedent not only for Toshiba but also for corporate Japan as a whole.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210228005077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 09:35:00 CEST | Press release
Agricultural innovation leader to contribute with agronomic expertise in building accurate crop health, pest forecasting and heat stress models India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
